EMA has published an overview of its key recommendations of 2024 regarding the authorisation and safety monitoring of veterinary medicines. In 2024, EMA recommended 25 veterinary medicines for marketing authorisation – the highest ever number of recommendations in a year. Of these, two had a new active substance which had not previously been authorised in a veterinary medicine in the EU. 14 were vaccines, including seven that had been developed by means of a biotechnological process.Among the medicines recommended for marketing authorisation in 2024, 13 were for food-producing animals, such as chickens, pigs and cattle, and 11 were for companion animals, such as dogs and cats.A selection of these recommendations can be found in the veterinary medicines highlights document published today.
Brief
On 23/01/2025, the European Medicines Agency (EMA) issued an update regarding Veterinary medicines in 2024. The EMA recommended a record-high number of veterinary medicines for marketing authorisation in 2024, with 25 products approved for use in both food-producing animals and companion animals. This includes two new active substances and 14 vaccines developed using biotechnological processes.
Highlights content goes here...
Purpose
The European Medicines Agency (EMA) has published an overview of its key recommendations for 2024 regarding the authorisation and safety monitoring of veterinary medicines. The objective is to provide a comprehensive summary of EMA’s recommendations for veterinary medicines, highlighting the significance of these developments in the field.
Effects on Industry
The high number of recommendations (25) for marketing authorisation of veterinary medicines marks a new record for the agency. This indicates a substantial increase in the development and approval of new animal health products, which will likely have a positive impact on the veterinary medicine industry. Companies involved in the research and development of veterinary medicines can expect an increased demand for their products, leading to potential growth opportunities.
Relevant Stakeholders
Veterinary medicine manufacturers, research institutions, farmers, pet owners, and regulatory authorities are among those affected by these recommendations. The publication of EMA’s key recommendations is particularly relevant for companies involved in the development of new animal health products, as it provides valuable information on the latest regulatory developments and trends.
Next Steps
The release of EMA’s overview of its key recommendations for 2024 serves as a guide for stakeholders to familiarize themselves with the latest advancements in veterinary medicine regulation. Companies can utilize this information to inform their future product development strategies and ensure compliance with evolving regulatory requirements. The selection of recommended medicines published in the veterinary medicines highlights document provides further insight into the types of products that have been recommended for marketing authorisation.
Any Other Relevant Information
The EMA’s focus on promoting animal health and well-being through the regulation of veterinary medicines is reflected in its efforts to facilitate access to safe and effective treatments. The agency’s recommendations are made with the goal of protecting both human and animal health, as well as ensuring the safety and quality of food products derived from treated animals. This commitment to maintaining high standards in animal health is likely to continue influencing industry developments and shaping regulatory priorities for years to come.
